Results 151 to 160 of about 28,654 (210)
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. [PDF]
PLoS One, 2016 Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T, GUARD-C Study Group. +11 moreeuropepmc +1 more sourceISARIC COVID-19 Clinical Data Report: Final report January 2020 – January 2023
, 2020 ISARIC Clinical Characterisation Group, Baillie JK, Baruch J, Beane A, Blumberg L, Bozza FA, Broadley T, Broadley T, Burrell A, Burrell A, Carson G, Citarella BW, Dunning J, Elotmani L, Garcia Barrio N, Garcia Barrio N, Goffard J, Hall M, Hall M, Hashmi M, Horby P, Jassat W, Kartsonaki C, Kumar Tirupakuzhi Vijayaraghavan B, Kumar Vecham P, Laouenan C, Lissauer S, Lissauer S, Martin-Loeches I, Mentre F, Morton B, Munblit D, Nekliudov NA, Nichol A, Ong DS, Panda PK, Jimenez MP, Petrovic M, Ramakrishnan N, Ramos GV, Roger C, Rojek A, Sandulescu O, Semple MG, Sharma P, Shrapnel S, Sigfrid L, Sim Lim Heng B, Singh BC, Somers E, Streinu-Cercel A, Taccone FS, Wei J, Wils E, Wong XC, Young K, Olliaro PL, Merson L. +57 moreeuropepmc +1 more sourceDetermining the return on investment of a global adaptive platform trial for critically ill patients during COVID-19: A value of implementation analysis in low- and middle-income countries and globally
Carrandi A, Beane A, Aryal D, Camirand-Lemyre F, Charles-Nelson A, Citarella BW, Fazla F, Grove A, Haniffa R, Hashmi M, Vijayaraghavan BKT, Lamontagne F, Nor MBM, Merson L, Hasan MS, Skouteris H, Higgins AM. +16 moreeuropepmc +1 more source
